Epinephrine injectors are life saving devices for people with food allergies and one company - Mylan Inc. - produces almost all of them. In this episode, listen to the highlights from a House Oversight and Government Reform Committee grilling of Mylan CEO Heather Bresch, and judge her justification for raising the EpiPen's price over 600% since EpiPen's competition was eliminated. Executive Producer: Anonymous Please support Congressional Dish: to contribute with PayPal or Bitcoin; click the PayPal "Make it Monthly" checkbox to create a monthly subscription to support Congressional Dish for each episode via Patreon Mail Contributions to: 5753 Hwy 85 North #4576 Crestview, FL 32536 Thank you for supporting truly independent media! Sound Clip Sources Hearing: House Oversight and Government Reform Committee, September 21, 2016. Witnesses , CEO of Mylan Inc. , Deputy Center Director for Regulatory Programs Clip Timestamps (In order of appearance in episode) 51:16 - Doug Throckmorton: Available epinephrine injectors 49:55 - Rep. John Mica (FL) and Doug Throckmorton: FDA won't discuss generic applications 0:35 - Chairman Jason Chaffetz (UT) - Introduction 9:25 - Elijah Cummings (MD): Mylan's actions that Congress is investigating 12:20 - Elijah Cummings: List of EpiPen price increases 4:10 - Jason Chaffetz: Executive compensation 16:55 - Elijah Cummings: Martin Shkreli called Congress "imbeciles" 24:10 - Heather Bresch: Introduction 28:16 - Heather Bresch: Mylan's profits from each EpiPen 47:43 - Rep. Elijah Cummings (MD) & Heather Bresch: Mylan did not give Congress requested documents 55:10 - Rep. Eleanor Holmes Norton & Heather Bresch: Will Mylan reduce the price of EpiPens? 1:23:26 - Rep. Scott DesJarlais (TN) & Heather Bresch: How long were the price increases going to continue? 1:32:10 - Rep. Gerald Connolly (VA) & Heather Bresch: Mylan's EpiPen is 94% of the epinephrine injector market. 1:56:55 - Rep. Stacey Plaskett (VI) & Heather Bresch: Why are customers paying so much for EpiPens? 2:01:04 - Rep. Mark Meadows (NC) & Heather Bresch: Everyone pays a different price in this system 2:51:15 - Rep. Bonnie Watson Coleman (NJ) & Heather Bresch: Mylan moved their headquarters to the Netherlands to pay less in U.S. taxes. 2:37:15 - Rep. Peter Welch & Heather Bresch: EpiPens cost much less in the Netherlands 1:03:15 - Rep. John Duncan (TN): Drug companies have manipulated the market. 1:44:25 - Tammy Duckworth (IL) & Heather Bresch: Mylan prohibited schools from buying from competitors 36:45 - Rep. Jason Chaffetz (UT) & Heather Bresch: Heather Bresch's explanation for why her mother used her position to get schools to buy EpiPens from Mylan 1:11:40 - Rep. Tim Walberg (MI) & Heather Bresch: Mylans plan would shift costs of EpiPens to government 1:21:16 - Rep. Stephen Lynch (MA) & Heather Bresch: Veterans Administration is able to negotiate it's drug prices, which makes them lower 53:35 - Rep. John Mica (FL) & Heather Bresch: Executive compensation at Mylan 59:19 - Rep. Eleanor Holmes Norton (DC) & Heather Bresch: What does Heather Bresch do to earn $18 million per year? 2:48:55 - Rep. Bonnie Watson Coleman (NJ) & Heather Bresch: Heather Bresch often uses a company private jet 2:13:50 - Rep. Mick Mulvaney (SC) & Heather Bresch: Mylan is getting what it deserves 3:08:08 - Rep. Glenn Grothman (WI) & Heather Bresch: Does Heather Bresch feel guilty? 3:39:40 - Rep. Jason Chaffetz & Heather Bresch: The numbers don't add up. 3:43:30 - Rep. Elijah Cummings (MD) Closing statement Additional Reading Article: by Jayne O'Donnell, USA Today, September 21, 2016. Article: by Olga Khazan, The Atlantic, August 24, 2016. Article: by Kelefa Sanneh, The New Yorker, February 5, 2016. Additional Information Law: OpenSecrets: Music Presented in This Episode Intro & Exit: by (found on by mevio) Cover Art Design by